First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

NCT04863287 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Lyme Disease

Interventions

BIOLOGICAL: 2217LS
OTHER: 0.9% Sodium Chloride (NaCl)

Sponsor

MassBiologics

Collaborators

[object Object]